Track market-moving stories before they get noisy

Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes.

, /PRNewswire/ -- TraceLink, the world's largest Agentic Business Network for the life sciences and healthcare supply chain, today announced an integration between its Drug Supply Chain Security Act (DSCSA) compliance solution and the pharmacy inventory management systems of Omnicell, Inc. (Nasdaq: OMCL), a leading healthcare technology provider focused on empowering autonomous medication management. This integration is expected to enable hospitals and health systems to manage product verification, traceability, and compliance as part of everyday medication receiving workflows.

Medication shipments received by a hospital or health system pharmacy must be verified, documented, incorporated into inventory, and made available for patient care. When verification or data discrepancies occur, pharmacy teams must also resolve compliance exceptions while maintaining accurate records for regulatory reporting. While the DSCSA established new standards for product verification and traceability, many pharmacy teams still rely on separate compliance tools and manual processes alongside their operational workflows. Managing compliance outside the pharmacy system can add complexity, consume valuable staff time, and create unnecessary interruptions during medication receiving.

Through this integration, hospitals can access TraceLink's DSCSA capabilities directly within Omnicell central pharmacy inventory management workflows. Pharmacy teams can verify serialized products, access traceability information, resolve product verification exceptions, complete compliance reporting, and document receiving activities as medications are received, intended to help reduce manual effort, eliminate disconnected processes, and streamline pharmacy operations without changing established workflows.

TraceLink's DSCSA solution is built on the Integrate-Once™ Agentic Business Network, which links more than 315,000 authenticated entities across life sciences and healthcare and supports hundreds of billions of annual supply chain transactions. By extending this trusted digital infrastructure into hospital pharmacy operations, healthcare organizations are expected to gain immediate access to accurate serialized medicine information exchanged across the broader life sciences supply chain, improve confidence in product authenticity while enabling faster product verification, more efficient compliance exception resolution, and targeted response when recalled products enter the pharmacy.

"Hospital pharmacies shouldn't have to choose between maintaining regulatory compliance and operating efficiently," said Shabbir Dahod, President and CEO of TraceLink. "By integrating TraceLink's trusted DSCSA network with Omnicell's central pharmacy inventory management workflows, we're able to embed verification and traceability directly into medication receiving so pharmacy teams spend less time managing compliance processes and more time ensuring medicines are available for patient care."

Together, TraceLink and Omnicell are working to help hospitals and health systems:

Verify serialized medicines within existing medication receiving workflows. Reduce manual effort associated with DSCSA compliance and audit-ready reporting. Resolve product verification and compliance exceptions more efficiently. Improve traceability to support faster identification of affected recalled products. Increase operational efficiency while supporting medication safety and availability. Sundar Tamma, Vice President of Product Management for Hospital Solutions at Omnicell, said, "Hospital pharmacies continue to face increasing operational demands with limited resources. The integration of TraceLink's solution expands the range of DSCSA integrations available to Omnicell Central Pharmacy Manager customers, providing additional options to support compliance while preserving the efficient workflows pharmacists depend on every day."

As hospital pharmacies continue to modernize medication management, the same trusted serialized medicine information should be able to support broader operational capabilities—including faster compliance exception resolution, targeted recall management, and future intelligent pharmacy workflows—without requiring separate data sources or disconnected compliance systems. This integration represents another step toward embedding trusted supply chain information directly into the systems healthcare providers use every day to deliver safe, efficient patient care.

Learn more about TraceLink's DSCSA compliance solutions for hospitals and health systems.

About TraceLink
TraceLink powers the transformation to an Agentic Supply Chain Operating Model, enabling organizations to perform and improve supply chain work across their business and trading partner networks. The Agentic Supply Chain Operating System, built on the OPUS Platform, brings together Agentic Business Processes, Agentic Control Towers, governed OPUS Agents, with the Integrate-Once™ Agentic Business Network to link systems, end-to-end business transactions, and collaborative peer-to-peer processes to create trusted, real-time operational context. In this agentic environment, humans and agents work together with greater speed, reasoning, control, and accountability to improve organizational productivity, service, inventory, working capital, cost, compliance, quality, resilience, and revenue performance.

Learn more at www.tracelink.com.

About Omnicell
Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities worldwide.

Learn more at https://www.omnicell.com/ 

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

SOURCE TraceLink, Inc.

Omnicell (OMCL - Free Report) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +95.83%. A quarter ago, it was expected that this Omnicell Inc. would post earnings of $0.33 per share when it actually produced earnings of $0.55, delivering a surprise of +66.67%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Omnicell, which belongs to the Zacks Medical Info Systems industry, posted revenues of $312.21 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.83%. This compares to year-ago revenues of $290.56 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Omnicell shares have lost about 8.6% since the beginning of the year versus the S&P 500's gain of 6.9%.

What's Next for Omnicell?While Omnicell has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Omnicell was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.47 on $312.99 million in revenues for the coming quarter and $1.97 on $1.24 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Senseonics Holdings (SENS - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 6.

This medical technology company is expected to post quarterly loss of $0.55 per share in its upcoming report, which represents a year-over-year change of -37.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Senseonics Holdings' revenues are expected to be $13.08 million, up 96.7% from the year-ago quarter.

Key Takeaways Omnicell is advancing autonomous pharmacy with new solutions and major health system wins. OMCL expanded its SaaS and Expert Services portfolio through acquisitions and new customer commitments. OMCL's 2026 guidance includes about $12M in tariff-related costs amid competitive pressure. Omnicell (OMCL - Free Report) is well poised to grow in the coming quarters as it continues to steadily advance the autonomous pharmacy industry-defined vision for delivering improved medication management outcomes. The company is expanding its SaaS and Expert Services portfolio via acquisitions and new platform launches. However, macroeconomic headwinds and competitive pressures could weigh on its operating performance.  

Over the past year, this Zacks Rank #3 (Hold) stock has had a remarkable run. OMCL shares have risen 51.6% compared to the industry’s 21.2% decline. The S&P 500 composite has grown 23.2% during the same time frame.

The renowned healthcare technology company has a market capitalization of $1.96 billion. OMCL’s earnings yield of 4.7% is comfortably above the industry’s negative 1% yield. In the trailing four quarters, Omnicell surpassed earnings estimates thrice and missed on one occasion, the average surprise being 34.7%.

Let’s delve deeper.Tailwinds for OMCL StockAutonomous Pharmacy Model Holds Potential: The industry-defined vision of Autonomous Pharmacy is a roadmap to improving operational efficiencies and ultimately targeting zero-error medication management. Over the past several years, the company has expanded its business from a single-point solution to a platform of products and services that will help further advance the vision. 

OMCL also secured several wins with major health systems and government health care facilities. Its ongoing R&D investments across Points of Care, Central Pharmacy and IV Compounding, Specialty Pharmacy and 340B Program and Ambulatory Care market categories are expected to deliver solutions that drive positive medication management outcomes for customers.

Robust Pipeline for SaaS and Expert Services Portfolio: Omnicell derives an increasing portion of revenues from its subscription-based SaaS and Expert Services offerings, which includes a combination of robotics, smart devices and intelligent software, all optimized by expert services. 

In recent years, the company has integrated three key acquisitions — Specialty Pharmacy Services, FDS Amplicare, and MarkeTouch Media. In the first quarter of 2026, several health systems committed to using Omnicell's inventory optimization service, alongside central pharmacy automation and point-of-care dispensing solutions.

Image Source: Zacks Investment Research

What Ails OMCL Stock?Escalating Expenses May Strain Margins: In response to changing tariffs, several foreign countries have imposed reciprocal duties on U.S.-manufactured goods. Changes in export or import regulations and other trade barriers may have an adverse effect on the company’s business. OMCL’s 2026 guidance incorporates an updated estimate of approximately $12 million in tariff-related costs impacting the P&L. 

Competitive Landscape: Omnicell faces intense competition in the medication management and supply-chain solutions market. Major direct competitors in the medication packaging solutions market pose threats as they spearhead several expansion programs. This increased competition could result in pricing pressure and a reduced margin, which would have an adverse impact on the company’s performance.

OMCL Stock Estimate TrendThe Zacks Consensus Estimate for OMCL’s 2026 earnings per share (EPS) has jumped $1.97 in the past 30 days. 

The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $1.24 billion, suggesting a 4.9% increase from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) . 

Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.

GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.

Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.